CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2019—Roche presented at the American Association for Cancer Research annual meeting the initial results from a phase one-b study evaluating the efficacy and safety for the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) as a first-line treatment option for people with advanced triple-negative breast cancer. Combination treatment demonstrated a confirmed objective response rate of 73 percent (95 percent CI, 53–88 percent), irrespective of tumor biomarker status. The median duration of follow-up was 6.1 months (range 3.1–10.6). Grade ≥ 3 adverse events occurred in 14 people (54 percent); the most common all-grade adverse events were diarrhea (88 percent; grade ≥ 3, 19 percent) and rash (69 percent; grade ≥ 3, 27 percent).